LI Chang-feng

486 total citations
8 papers, 400 citations indexed

About

LI Chang-feng is a scholar working on Molecular Biology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, LI Chang-feng has authored 8 papers receiving a total of 400 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 6 papers in Cancer Research and 1 paper in Pulmonary and Respiratory Medicine. Recurrent topics in LI Chang-feng's work include Cancer-related molecular mechanisms research (5 papers), MicroRNA in disease regulation (5 papers) and Circular RNAs in diseases (4 papers). LI Chang-feng is often cited by papers focused on Cancer-related molecular mechanisms research (5 papers), MicroRNA in disease regulation (5 papers) and Circular RNAs in diseases (4 papers). LI Chang-feng collaborates with scholars based in China. LI Chang-feng's co-authors include Tiancheng Zhao, Yongchao Li, Dayong Ding, Dandan Li, Bin Zhang, Lei Yang, Yun Wang, Dandan Li, Bin Zhang and Libo Sun and has published in prestigious journals such as Journal of Cellular Biochemistry, Clinical Science and International Journal of Oncology.

In The Last Decade

LI Chang-feng

8 papers receiving 395 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
LI Chang-feng China 7 335 307 37 28 18 8 400
Fushuang Zheng China 9 255 0.8× 219 0.7× 23 0.6× 23 0.8× 14 0.8× 18 309
Suxia Luo China 11 225 0.7× 215 0.7× 15 0.4× 34 1.2× 15 0.8× 15 294
Yangchao Wei China 8 255 0.8× 149 0.5× 20 0.5× 54 1.9× 17 0.9× 8 322
Xin Yuan China 10 234 0.7× 189 0.6× 21 0.6× 21 0.8× 24 1.3× 22 302
Yi Hou China 11 242 0.7× 203 0.7× 28 0.8× 30 1.1× 18 1.0× 20 344
Zhang Yl China 9 217 0.6× 164 0.5× 21 0.6× 38 1.4× 28 1.6× 40 348
Xiubao Ren China 7 388 1.2× 380 1.2× 16 0.4× 30 1.1× 31 1.7× 8 452

Countries citing papers authored by LI Chang-feng

Since Specialization
Citations

This map shows the geographic impact of LI Chang-feng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by LI Chang-feng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites LI Chang-feng more than expected).

Fields of papers citing papers by LI Chang-feng

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by LI Chang-feng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by LI Chang-feng. The network helps show where LI Chang-feng may publish in the future.

Co-authorship network of co-authors of LI Chang-feng

This figure shows the co-authorship network connecting the top 25 collaborators of LI Chang-feng. A scholar is included among the top collaborators of LI Chang-feng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with LI Chang-feng. LI Chang-feng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

8 of 8 papers shown
1.
Wang, Yun, LI Chang-feng, Libo Sun, & Yongchao Li. (2020). microRNA-4270-5p inhibits cancer cell proliferation and metastasis in hepatocellular carcinoma by targeting SATB2. Human Cell. 33(4). 1155–1164. 17 indexed citations
2.
Chang-feng, LI, Dayong Ding, Yongjian Gao, & Yongchao Li. (2020). MicroRNA‑3651 promotes colorectal cancer cell proliferation through directly repressing T‑box transcription factor 1. International Journal of Molecular Medicine. 45(3). 956–966. 7 indexed citations
3.
Li, Yongchao, et al.. (2019). A novel circFMN2 promotes tumor proliferation in CRC by regulating the miR-1182/hTERT signaling pathways. Clinical Science. 133(24). 2463–2479. 69 indexed citations
4.
Chang-feng, LI, Yongchao Li, Yun Wang, & Libo Sun. (2018). The Effect of LncRNA H19/miR-194-5p Axis on the Epithelial-Mesenchymal Transition of Colorectal Adenocarcinoma. Cellular Physiology and Biochemistry. 50(1). 196–213. 44 indexed citations
5.
Ding, Dayong, LI Chang-feng, Tiancheng Zhao, et al.. (2018). LncRNA H19/miR-29b-3p/PGRN Axis Promoted Epithelial-Mesenchymal Transition of Colorectal Cancer Cells by Acting on Wnt Signaling.. PubMed. 41(5). 423–435. 150 indexed citations
6.
Wang, Yun, et al.. (2017). Procaine is a specific DNA methylation inhibitor with anti‐tumor effect for human gastric cancer. Journal of Cellular Biochemistry. 119(2). 2440–2449. 59 indexed citations
7.
Chang-feng, LI, Mitsuhiro Kida, Hiroshi Yamauchi, et al.. (2014). Diagnostic Ability and Factors Influencing the Accuracy of EndoscopicUltrasonography-guided Fine-needle Aspiration for Solid Lesions In andAdjacent to the Gastrointestinal Tract.. Biomedical Research-tokyo. 25(4). 0. 1 indexed citations
8.
Wu, Xiaodong, Siqi Zhang, LI Chang-feng, et al.. (2012). The tumor suppressor gene RhoBTB1 is a novel target of miR-31 in human colon cancer. International Journal of Oncology. 42(2). 676–682. 53 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026